5 days ago
HomeMarket NewsStocks NewsGlenmark Pharma stages smart recovery in Q3 with ₹348-crore net profit on higher revenues
EBITDA zoomed to ₹600.3 crore in the third quarter over a loss of ₹208.7 crore in the year-ago quarter. Shares of Glenmark Pharmaceuticals Ltd ended at ₹1,321.35, down by ₹88.55, or 6.28%, on the BSE.
Glenmark Pharmaceuticals Ltd on Friday (February 14) reported a net profit of ₹347.9 crore for Q3FY25, recovering from a net loss of ₹351.3 crore.
Revenue from operations surged 35.1% to ₹3,387.6 crore against ₹2,506.7 crore in the corresponding period of the preceding fiscal.
Also Read: Dish TV India Q3 Results | Net loss widens to ₹47 crore as revenue declines 21%
At the operating level, EBITDA zoomed to ₹600.3 crore in the third quarter over a loss of ₹208.7 crore in the year-ago quarter. The EBITDA margin stood at 17.7% in the reporting quarter. EBITDA is earnings before interest, tax, depreciation, and amortisation.
The results came after the close of the market hours. Shares of Glenmark Pharmaceuticals Ltd ended at ₹1,321.35, down by ₹88.55, or 6.28%, on the BSE.
Also Read: Easy Trip Q3 Results | Net profit, margin decline despite 172% rise in hotel bookings
(Edited by : Shoma Bhattacharjee)
